- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
- Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
- Aurinia Provides Update on Proxy Statement
- Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf
- Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
- Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
- Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
More ▼
Key statistics
On Friday, Aurinia Pharmaceuticals Inc (AUPH:NMQ) closed at 5.30, 12.53% above the 52 week low of 4.71 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.34 |
---|---|
High | 5.37 |
Low | 5.25 |
Bid | 5.28 |
Offer | 5.32 |
Previous close | 5.39 |
Average volume | 962.98k |
---|---|
Shares outstanding | 143.02m |
Free float | 132.91m |
P/E (TTM) | -- |
Market cap | 780.89m USD |
EPS (TTM) | -0.4363 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼